The main endpoints include cardiovascular morbidity and mortality, including stroke, heart attack, and heart failure. People with ISH have an increased cardiovascular risk. While we know that people in the early stages of ISH are at increased risk for serious consequences including heart attack, heart failure, and stroke, the benefit of treating these patients has never been proven in a prospective clinical trial. In the past, physicians focused primarily upon reducing diastolic pressure of patients with hypertension. The systolic pressure occurs when the heart contracts.
Diastolic pressure occurs when the heart is in the relaxed state.
In the study, omapatrilat will be titrated to 40 milligrams once daily. Omapatrilat is well suited for treating ISH because of its potent effect on both systolic and diastolic blood pressure. This novel agent may help patients lower systolic blood pressure to the goal, as established by international guidelines. In addition to ISH, omapatrilat is being studied in the treatment of hypertension and heart failure in a broad range of cardiovascular patients. Italicized product names are registered trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries.